Search Results for "Skyla"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for Skyla. Results 1 to 6 of 6 total matches.
See also: levonorgestrel
A New Low-Dose Levonorgestrel-Releasing IUD (Skyla)
The Medical Letter on Drugs and Therapeutics • Mar 18, 2013 (Issue 1412)
A New Low-Dose Levonorgestrel-Releasing IUD (Skyla) ...
The FDA recently approved Skyla (Bayer), the first new
intrauterine device (IUD) in the US in 12 years. It
releases levonorgestrel, a synthetic progestin, over a
period of 3 years. A table summarizing contraceptive
methods available in the US appears on page 22.
Liletta - A Third Levonorgestrel-Releasing IUD
The Medical Letter on Drugs and Therapeutics • Jul 06, 2015 (Issue 1472)
— Liletta is the same size as Mirena
and slightly larger than Skyla. It has a 32x32mm T-shaped
plastic ...
The FDA has approved Liletta, an intrauterine
device (IUD) that releases the synthetic progestin
levonorgestrel, for prevention of pregnancy for up to
3 years. The fourth IUD to be approved in the US, and
the third that releases levonorgestrel, Liletta is
comarketed by Actavis and Medicines360, a nonprofit
women's health pharmaceutical company. The wholesale
cost of Liletta is similar to that of other IUDs (see
Table 1), but the manufacturer offers programs that
significantly reduce the cost for commercially-insured
patients and clinics serving low-income women.
Kyleena - Another Hormonal IUD
The Medical Letter on Drugs and Therapeutics • Feb 27, 2017 (Issue 1515)
0.15 52 mg 684.40
(Allergan/Actavis)
Mirena (Bayer)5 5 years 0.2 52 mg 858.30
Skyla (Bayer) 3 years ...
The FDA has approved Kyleena (Bayer), an intrauterine
device (IUD) that releases the synthetic progestin
levonorgestrel, for prevention of pregnancy. It is the
fourth levonorgestrel-releasing IUD to be approved in
the US. Like Mirena, which has been available since
2000, Kyleena is approved for up to 5 years of use.
Phexxi - A Nonhormonal Contraceptive Gel
The Medical Letter on Drugs and Therapeutics • Aug 24, 2020 (Issue 1605)
IUDs
Kyleena (Bayer)
Liletta (Abbvie/Medicines 360)
Mirena (Bayer)
Skyla (Bayer)
0.2%
0.1%
0.1 ...
The FDA has approved Phexxi (Evofem), a
nonhormonal prescription-only vaginal gel containing
lactic acid, citric acid, and potassium bitartrate, for
prevention of pregnancy. The gel is intended for on-demand
contraception; it is not effective when used
after intercourse. It was previously approved for
use as a vaginal lubricant (Amphora), but was never
marketed.
Miudella – A Lower-Dose Copper IUD
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025 (Issue 5106)
, was approved in 1984. Four hormonal
IUDs (Mirena, Liletta, Skyla, Kyleena) that release
the progestin ...
Miudella (Sebela), a copper intrauterine device (IUD),
has been approved by the FDA for prevention of
pregnancy for up to 3 years. Miudella is the second
copper IUD to be approved in the US; ParaGard, which
contains more copper and is approved for up to 10
years of use, was approved in 1984. Four hormonal
IUDs (Mirena, Liletta, Skyla, Kyleena) that release
the progestin levonorgestrel are also available for
pregnancy prevention (see Table 2).
Med Lett Drugs Ther. 2025 Apr 28;67(5106):1-2 doi:10.58347/tml.2025.5106a | Show Introduction Hide Introduction
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023 (Issue 1676)
)
Levonorgestrel 13.5 mg
(Skyla)
0.1%
0.2%
0.4%
0.1%
0.2%
0.3%
Mirena and Liletta approved for
up to 8 ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 doi:10.58347/tml.2023.1676a | Show Introduction Hide Introduction